Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease.
OBJECTIVE
Interleukin 31 (IL31), primarily expressed in activated lymphocytes, signals through a heterodimeric receptor complex consisting of the IL31 receptor alpha (IL31Ralpha) and the oncostatin M receptor (OSMR). The aim of this study was to analyse IL31 receptor expression, signal transduction, and specific biological functions of this cytokine system in intestinal inflammation.


METHODS
Expression studies were performed by RT-PCR, quantitative PCR, western blotting, and immunohistochemistry. Signal transduction was analysed by western blotting. Cell proliferation was measured by MTS assays, cell migration by restitution assays.


RESULTS
Colorectal cancer derived intestinal epithelial cell (IEC) lines express both IL31 receptor subunits, while their expression in unstimulated primary murine IEC was low. LPS and the proinflammatory cytokines TNF-alpha, IL1beta, IFN-gamma, and sodium butyrate stimulation increased IL31, IL31Ralpha, and OSMR mRNA expression, while IL31 itself enhanced IL8 expression in IEC. IL31 mediates ERK-1/2, Akt, STAT1, and STAT3 activation in IEC resulting in enhanced IEC migration. However, at low cell density, IL31 had significant antiproliferative capacities (p<0.005). IL31 mRNA expression was not increased in the TNFDeltaARE mouse model of ileitis but in inflamed colonic lesions compared to non-inflamed tissue in patients with Crohn's disease (CD; average 2.4-fold increase) and in patients with ulcerative colitis (UC; average 2.6-fold increase) and correlated with the IL-8 expression in these lesions (r = 0.564 for CD; r = 0.650 for UC; total number of biopsies analysed: n = 88).


CONCLUSIONS
IEC express the functional IL31 receptor complex. IL31 modulates cell proliferation and migration suggesting a role in the regulation of intestinal barrier function particularly in intestinal inflammation.
Dambacher
Julia
J
University Hospital Munich-Grosshadern, Department of Medicine II, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany.
Beigel
Florian
F
Seiderer
Julia
J
Haller
Dirk
D
Göke
Burkhard
B
Auernhammer
Christoph J
CJ
Brand
Stephan
S
D000818:Animals; D002455:Cell Division / Q000276:immunology; D002460:Cell Line; D002465:Cell Movement / Q000276:immunology; D003106:Colon / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000276:immunology; D004847:Epithelial Cells / Q000276:immunology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000276:immunology*; D007371:Interferon-gamma / Q000032:analysis; D053583:Interleukin-1beta / Q000032:analysis; D007378:Interleukins / Q000276:immunology*; D007413:Intestinal Mucosa / Q000276:immunology; D007422:Intestines / Q000166:cytology / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D020928:Mitogen-Activated Protein Kinases / Q000276:immunology*; D010766:Phosphorylation; D012333:RNA, Messenger / Q000032:analysis; D018123:Receptors, Interleukin / Q000032:analysis; D053677:Receptors, Oncostatin M / Q000276:immunology; D050791:STAT Transcription Factors / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D015854:Up-Regulation / Q000276:immunology
C502187:IL31 protein, human; C502188:IL31RA protein, human; D053583:Interleukin-1beta; D007378:Interleukins; D012333:RNA, Messenger; D018123:Receptors, Interleukin; D053677:Receptors, Oncostatin M; D050791:STAT Transcription Factors; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D020928:Mitogen-Activated Protein Kinases